Biohaven Pharmaceutical Holding Co. Ltd. (BHVN)
| Market Cap | 4.81B |
| Revenue (ttm) | 63.63M |
| Net Income (ttm) | -766.80M |
| Shares Out | 58.73M |
| EPS (ttm) | -13.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $72.74 |
| Previous Close | $74.40 |
| Change ($) | -1.67 |
| Change (%) | -2.24% |
| Day's Open | 73.32 |
| Day's Range | 72.74 - 74.32 |
| Day's Volume | 95,000 |
| 52-Week Range | 37.92 - 100.77 |
NEW HAVEN, Conn., April 13, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume.
NEW HAVEN, Conn., April 7, 2021 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd.
MOORESVILLE, N.C., April 6, 2021 /PRNewswire/ -- Rick Ware Racing announced today its partnership with Biohaven's Nurtec® ODT (rimegepant) and Nine Line Apparel to honor the nation's fallen service memb...
Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) has enrolled the first patient in a Phase 2/3 trial evaluating oral zavegepant for migraine's preventive treatment, triggering a milestone funding pay...
NEW HAVEN, Conn., March 29, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceuticals CEO on how Nurtec migraine drug punches above its weight
Biohaven Pharmaceuticals CEO Vlad Coric said the company's digital-first and patient-focused strategy is giving it an edge against competitors in marketing the migraine drug Nurtec.
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders took advantage of initial public offerings in the past week.
NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
NEW HAVEN, Conn., March 11, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
NEW HAVEN, Conn., March 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
NEW HAVEN, Conn., March 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
Agreement enables Biohaven to exercise option on up to three of Artizan's candidates for the treatment of inflammatory bowel disease
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -25.26% and 0.30%, respectively, for the quarter ended December 2020.
Shares of Biohaven Pharmaceutical (NYSE:BHVN) decreased 0.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 5.61% year over year to ($2.69), wh...
NEW HAVEN, Conn., March 1, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of ...
NEW HAVEN, Conn., Feb. 23, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product...
Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) hyperimmune globulin mimic developed with Biohaven's MATE platform has demonstrated functional binding and neutralization of the SARS-CoV-2 virus, i...
Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NEW HAVEN, Conn., Feb. 22, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product...
NEW HAVEN, Conn., Feb. 8, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-st...
NEW HAVEN, Conn., Jan. 25, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-s...
Treating The Causes Of Alzheimer's Disease: The Case For Anavex 2-73
Biohaven Pharmaceuticals said Monday its experimental Alzheimer's treatment, known as troriluzole, failed during a midstage testing process. The news sent BHVN stock into a dive Tuesday.
Biohaven (BHVN) announces preliminary data from a phase II/III AD study demonstrating troriluzole's failure to achieve statistical improvement in primary endpoints.
Alzheimer's claims another drug candidate.
MOORESVILLE, N.C., Jan. 18, 2021 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Cody Ware will pilot the Nurtec® ODT (rimegepant) #51 Chevrolet Camaro for Rick Ware Racing dur...
NEW HAVEN, Conn., Jan. 18, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it has completed a focused analysis of the topline co-primary and key secon...
NEW HAVEN, Conn., Jan. 7, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") today announced the acquisition of the remaining 58% interest of Kle...
Biohaven (BHVN) initiates enrollment in a phase III study to evaluate troriluzole as adjunctive treatment for patients with obsessive-compulsive disorder.
NEW HAVEN, Conn., Jan. 4, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") today announced that it has commenced enrollment in a Phase 3 clinical trial assessi...
Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.
NEW HAVEN, Conn., Dec. 16, 2020 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that The Lancet published the company's positive results from a Phase 3 clinica...
Biohaven is establishing a comprehensive suite of migraine medicines. The company has an exciting pipeline of interesting late stage products.
MOORESVILLE, N.C., Dec. 2, 2020 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announces today that Nurtec™ ODT (rimegepant) will be the primary partner for the No. 51 Rick Ware Racing entry durin...
TOKYO and CAMBRIDGE, England, Dec. 1, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Ph...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...
"I hope that in six months or so from now that we will be the first oral CGRP with the indication for the prevention of migraine," Biohaven CEO Vlad Coric said.
Biohaven Pharmaceutical CEO on efforts to prevent migraine with oral CGRP
CEO Vlad Coric said Biohaven, a biotech firm with a new product to treat migraines, plans to have a drug that can prevent migraines in the next sixth months.
NEW HAVEN, Conn., Nov. 16, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product...
NEW HAVEN, Conn., Nov. 11, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class ther...
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) CEO Vlad Coric on Q3 2020 Results - Earnings Call Transcript
Shares of Biohaven Pharmaceutical (NYSE:BHVN) traded flat in pre-market trading after the company reported Q3 results.
Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
About BHVN
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indi... [Read more...]
| Industry Biotechnology | IPO Date May 4, 2017 |
| CEO Vlad Coric | Employees 825 |
| Stock Exchange NYSE | Ticker Symbol BHVN |
Analyst Forecasts
According to 11 analysts, the average rating for BHVN stock is "Strong Buy." The 12-month stock price forecast is 101.91, which is an increase of 40.11% from the latest price.